As a REIT, Equity One, Inc. (NYSE:EQY) would not be subject to federal tax to the extent that it distributes at least 90% of its taxable income to its shareholders. Equity One, a real estate investment trust (REIT), engages in the ownership, management, acquisition, renovation, and development of neighborhood and community shopping centers in the United States. Equity One was founded in 1992 and is based in North Miami Beach, Florida with an additional office in Israel.



Equity One, Inc. announced that it has entered into an agreement to sell 36 shopping centers comprising approximately 3.9 million square feet for $473.1 million to Blackstone Real Estate Partners VII. These assets were encumbered by mortgage loans having an aggregate principal balance of approximately $177.4 million as of June 30, 2011.

"We are very pleased to enter into this transaction with Blackstone," said Jeff Olson, Chief Executive Officer of Equity One. "Together with our $600 million purchase of Capital & Counties and other recent acquisitions, this sale significantly advances our strategic plan to concentrate our portfolio in the urban retail markets of New York, Miami, Boston, San Francisco and Los Angeles."

The shopping centers are predominately located in the Atlanta, Tampa and Orlando markets, with additional properties located in North Carolina, South Carolina, Alabama, Tennessee and Maryland. The portfolio generated net operating income of approximately $35.4 million for the twelve-month period ended June 30, 2011 and was 91% occupied as of June 30, 2011. A complete listing of the disposition assets is provided in Exhibit 1 to this press release. Equity One intends to use the proceeds from the sale to retire debt, fund its redevelopment pipeline, for future acquisitions and other corporate purposes.

For more information about Equity One, please visit www.equityone.net



**************************

Enzo Biochem Inc. (ENZ)
Biotechnology, which the United Nations Convention on Biological Diversity defines as "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use," is not really a new scientific field. For example, the production of beer by fermenting malt or barley with the use of yeast cells has been in existence for thousands of years. In medicine, biotechnology has been part of the discipline since the 1920s when penicillin started to be manufactured with the use of a fungus, Penicillium notatum. Likewise, vaccines that consist of parts of or whole live microorganisms with attenuated virulence have been in existence for many decades now.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since ENZ was founded in 1976, their strategic focus has been on the development of enabling technologies in the life sciences field.

Enzo Biochem Inc. recently announced that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.

The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D'Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.

Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary's operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo's presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.

For more information please visit: www.enzo.com

**********************

Cleantech Transit, Inc. (CLNO)

Cleantech Transit, Inc. is in the business of producing and conserving power. Cleantech Transit produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind. Cleantech Transit's goal is to use innovative technologies to reduce electricity consumption and dependence on carbon based energy. Cleantech Transit, Inc. was founded in 2006 and is based in Scottsdale, Arizona.

Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company's ability to earn in 25% of the 500KW Merced Project.

The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.






Read the full article and the disclaimer atennyotcstock.com/?p=17300